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Abstract
Human central diabetes insipidus (CDI) is a neurobiological syndrome characterized by the 
presence of hypotonic polyuria, hypernatremia, and polydipsia. CDI can be acquired (aCDI) 
as the result of brain damage to magnocellular neurosecretory cells or fibers that constitute 
the hypothalamic-neurohypophyseal system or can be caused by genetic disorders (heredi-
tary CDI). aCDI can be experimentally induced by various surgical interventions, including 
neurohypophysectomy, pituitary stalk compression (PSC), hypophysectomy, and hypotha-
lamic mediobasal lesions. CDI has been associated with a deficient production of arginine 
vasopressin (AVP) (the antidiuretic hormone secreted by magnocellular system), while 
more recently, aCDI animal studies also suggest the possible involvement of oxytocin (OT) 
(a natriuretic-promoting hormone secreted by neurosecretory systems) and other factors 
related to serum fluid concentration. Both humans and animals with aCDI may benefit 
from the combined administration of AVP and OT and, importantly, from a low-sodium 
diet. Moreover, increased OT levels are observed in Brattleboro rats (with mutated AVP 
gene), which may explain the regulatory hydromineral capacity shown by these animals 
after hydromineral challenges. In short, the symptoms shown by the different CDI animal 
models suggest the involvement of additional factors besides the absence of AVP, which 
appear to depend on the particular neurobiological systems affected in each case.
Keywords: central diabetes insipidus, hypophysectomy, neurohypophysectomy, pituitary 
stalk compression, mediobasal hypothalamic lesion, arginine vasopressin, oxytocin, 
hypernatremia, low-sodium diet
1. Introduction
The term diabetes refers to a wide variety of syndromes, including diabetes insipidus (DI), 
which share in common the copious production of urine (polyuria). DI is characterized by the 
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excretion of abundant diluted, “tasteless” urine and was first described by Willis in the sev-
enteenth century. The incidence of this disorder is around 1:25,000 cases, with no statistically 
significant differences between males and females.
In general, two main DI types can be distinguished: one that is related to deficient secre-
tion of the antidiuretic hormone arginine vasopressin (AVP), which is better documented 
and referred to as central, neurogenic, neurohypophyseal, or hypothalamic DI, and another 
characterized by renal insensitivity to the antidiuretic effect of AVP, designated nephrogenic 
DI [1–5].
This chapter starts with a description of the general characteristics of central diabetes 
insipidus (CDI), including its symptoms, the brain systems involved, and the etiologies of 
acquired and hereditary CDI. We then review the main animal models of acquired (neuro-
hypophysectomy, pituitary stalk compression (PSC), hypophysectomy, and hypothalamic 
mediobasal lesions) and hereditary (Brattleboro rats) CDI. Finally, data from animal and 
human studies are discussed in relation to the therapeutic usefulness of oxytocin and a low-
sodium diet.
2. Central diabetes insipidus: an overview
2.1. General characteristics of human central diabetes insipidus
CDI is a neurobiological syndrome characterized by the excretion of copious amounts of 
diluted urine, i.e., containing a reduced concentration of electrolytes (mainly Na+). The excre-
tory response in CDI is associated with a rise in serum osmolality (hyperosmolality) and 
sodium concentration (hypernatremia) and with the intake of large amounts of water (poly-
dipsia) (see Table 1) [2, 5, 6].
2.2. Neuroendocrine control of antidiuresis and electrolyte excretion
Urine and electrolyte excretions by the kidneys are related to the hormones AVP and oxy-
tocin (OT), among other endocrine mechanisms [7, 8]. AVP and OT have similar chemical 
structures and are both nonapeptides, differing in amino acids at positions 3 and 8 (Figure 1). 
They are synthesized with their corresponding carriers, neurophysins I and II, respectively, 
Diabetes insipidus Normal
Urine volume (liters/day) Up to 20 1–1.5
Urine osmolality (mOsm/L) <300 300–1400
Serum osmolality (mOsm/kg) >300 280–300
Serum sodium (mEq/L) >145 135–145
Table 1. General characteristics of patients with CDI in comparison to a healthy population.
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and human genes for OT-neurophysin I and AVP-neurophysin II are both on chromosome 20, 
separated by only 12 kb of intergenic sequences [9].
Both hormones are synthesized in the perikarya of the magnocellular neurons of hypotha-
lamic paraventricular (PVN) and supraoptic nuclei (SON). There is a predominance of AVP-
producing cells in the SON, while oxytocinergic cells are confined to the rostral and dorsal 
nucleus region. For its part, the magnocellular PVN possesses a similar number of oxytocin-
ergic and vasopressinergic neurons; its anteromedial portion contains mostly OT neurons, 
whereas its anterolateral portion contains an inner part with AVP neurons, surrounded by 
a ring of OT neurons. Less densely packed groups of AVP and OT neurons are found in 
posterior PVN. The axons of this complex (magnocellular PVN and SON) pass through the 
inner part of the median eminence, forming the neurohypophyseal stalk, and terminate in the 
neurohypophysis. Axonal swellings have been identified near fenestrated capillaries in both 
the median eminence and neurohypophysis, permitting access of these neurohormones to the 
bloodstream [10].
Hyperosmolality, hypernatremia, and hypovolemia (isotonic loss of fluid and electrolytes) 
are the main triggers of AVP and OT secretion [7, 11, 12]. After AVP is released into the blood, 
it acts by binding to AVP receptor 2 (AVPR2) on the basal surface of renal collecting tubule 
cells, triggering an intracellular signaling cascade. This concludes with activation of a cyclic 
adenosine monophosphate kinase pathway, increasing the production and insertion of aqua-
porin-II (AQP2) channels into the cell membrane. This in turn leads to passive water resorp-
tion from the lumen of the nephron into the cells of the collecting duct along an osmotic 
gradient [12–15]. The consequent excretion of concentrated urine is a survival mechanism for 
prolonged starvation periods. Conversely, diluted urine is excreted in the absence of AVP [8]. 
The neurohormone OT is especially involved in the excretion of body sodium or natriuresis 
[11, 16–20]. This secretion appears to be stimulated by increases in the glomerular filtration 
rate [21] and reductions in tubular sodium reabsorption [22]. These effects are mediated by 
actions on OT receptors present in the kidney and also, indirectly, by cardiac secretion of 
(A) Arginine Vasopressin 
Cys -Tyr -Phe-Gln -Asn -Cys -Pro.Arg -Gly -NH2
(B) Oxytocin
Cys -Tyr -Ile -Gln -Asn -Cys -Pro -Leu -Gly -NH2
Figure 1. Chemical structure of (A) AVP and (B) OT. AVP is formed by amino acids cysteine-tyrosine-phenylalanine-
glutamine-asparagine-cysteine-proline-arginine-glycine-NH
2
 and OT by cysteine-tyrosine-isoleucine-glutamine-asparagine-
cysteine-proline-leucine-glycine-NH
2
. In both cases, a ring of amino acids 1–6 is formed by a disulfide bond.
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atrial natriuretic peptide (ANP) [11]. OT may also act on AVPR2 to exert antidiuretic effects 
(Figure 2) [23, 24].
Both AVP and OT have been proposed to have synergic effects, with the natriuretic effect of 
their combined administration having a greater intensity and longer duration than the sum of 
the effects of each neurohormone [25, 26].
It has been reported that other hormones are involved in hydromineral regulatory processes, 
such as ANP co-localized with OT in hypothalamic magnocellular neurons (see Bundzikova 
et al. [27] for a review).
2.3. Etiological bases of human CDI
2.3.1. Acquired CDI
The most common CDI follows brain injury or surgery in the region of the pituitary and 
hypothalamus with damage to mediobasal hypothalamus (MBH), hypophyseal stalk, infun-
dibulum, or the pituitary gland itself [28–32].
Figure 2. Upper: Sagittal section of the brain (left) and kidney (right). Lower (magnified insets): AVP and OT neurosecretory 
system (left) and simplified structure of a nephron (right).
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CDI manifestations can be transient, permanent, or triphasic. Transient CDI starts with an 
abrupt onset of polyuria and polydipsia within 24–48 h of surgery/trauma and gradually 
resolves over a 3- to 5-day period [13, 30]. In permanent CDI, polyuric and polydipsic symp-
toms arise immediately and remain chronic in the absence of treatment [2, 33]. Triphasic CDI 
(Figure 3) was first described by Fisher and Ingram [35]. The first phase, clinically identical 
to transient CDI, starts with polyuria and polydipsia within 24 h of surgery, followed by an 
interphase (oliguric phase), with a reduction in urine excretion volume and water intake, and 
a final persistent phase of polyuria and polydipsia [13, 28, 36].
The regulatory and behavioral symptoms of CDI may be explained by the arrangement of 
hypothalamic-neurohypophyseal fibers. In this way, CDI with only transient polydipsia may 
be produced by lesions located ventrally to the median eminence, possibly attributable to secre-
tion into the median eminence area of the hormonal contents of magnocellular PVN and SON 
neurons. Distinct effects are observed after damage to the whole hypothalamic-neurohypoph-
yseal tract, which results in a consistently increased water intake from the onset (permanent 
CDI). Finally, the presence of intact/preserved axons or the release of AVP by degenerating 
terminals is considered responsible for the oliguric interphase in triphasic CDI [28, 37, 38].
2.3.2. Hereditary CDI
Hereditary CDI (hCDI) accounts for only 1–2% of all cases [5, 39]. It is frequently related to 
mutations in the AVP-neurophysin II gene, located distally at the short arm of chromosome 20 
(20p13) and containing three exons. The signal peptide AVP and the NH
2
-terminal region of 
Figure 3. Water intake and urine volume in triphasic CDI (adapted from Ref. [34] with permission from Elsevier).
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neurophysin II are encoded by exon A of the AVP-neurophysin II gene, and the central region 
of neurophysin II is encoded by exon B, while the COOH-terminal region of neurophysin II 
and glycopeptide are encoded by exon C.
More than 50 AVP mutations segregating with autosomal dominant or autosomal recessive 
CDI have been described (see http://omim.org/entry/125700). Limited capacity to secrete AVP 
during severe dehydration is maintained by patients with autosomal dominant CDI, whose 
polyuric-polydipsic symptoms generally appear after the age of 1 year, when adults are more 
likely to comprehend the child’s requests for water. There have also been reports of three fami-
lies with autosomal recessive neurohypophyseal DI in which the patients were homozygous or 
compound heterozygotes for AVP mutations. Two of these families were phenotypically charac-
terized by severe polyuria, polydipsia, dehydration, and early onset in the first 3 months of life.
3. Animal models of CDI
3.1. Animal models of acquired CDI
Acquired CDI (aCDI) can be experimentally induced in animals by surgical interventions that 
produce a deficit in the secretion of both AVP and OT, including mediobasal hypothalamic 
(MBH) lesions, sectioning of hypothalamic-neurohypophyseal tract, pituitary stalk compres-
sion, hypophysectomy, and neurohypophysectomy (see Bernal et al. [34] for a review).
3.1.1. Neurohypophysectomy and pituitary stalk compression
After exposure of the pituitary gland through a parapharyngeal approach, a small incision 
is made in the caudal tip of the anterior lobe. This reveals the underlying posterior pituitary 
lobe, which is then removed by gentle suction. Given the technical difficulty of a specific neu-
rohypophysectomy (neurohypox), selective deafferentation of the neurohypophysis has been 
induced by some authors (pituitary stalk compression). For this purpose, anesthetized rats are 
mounted on a stereotaxic frame with nose down 3.5 mm, the skull is opened by removing a 
small square of the bone, and a triangle-shaped wire is then lowered in coronal plane 4.0 mm 
caudal to bregma in the midline until it reached the skull floor. The wire is held against the 
skull for 30 s and then removed, evaluating the absence of tissue damage to the anterior pitu-
itary lobe by microscopic examination and measurements of plasma levels of adenohypophy-
seal hormones in terminal blood samples.
Neurohypox and pituitary stalk compression (PSC) have been found to interrupt the secretion 
of AVP and OT, increase urine excretion and water intake, and reduce the excretion of sodium 
[40, 41]. In addition, salt loading (administration of hypertonic NaCl) increased serum osmo-
lality to a greater degree in PSC animals than in sham-operated animals [42].
In earlier studies in neurohypox dogs, OT administration raised renal clearances [43] and AVP 
plus OT administration increased sodium excretion [44]. In a study of neurohypox rats, Balment 
and associates [40] found that AVP administration reduced urine flow and produced a small 
increase in sodium excretion. Importantly, however, OT administration within the physiological 
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range enhanced the natriuretic response to AVP, reversing the renal sodium excretion deficit in 
neurohypox rats. Moreover, the combined use of OT and AVP at low doses that do not sepa-
rately promote significant body sodium excretion revealed a marked synergic natriuretic effect 
superior to the sum of their individual effects. Consequently, the reduced natriuretic capacity of 
neurohypox animals appears to be attributable to a lack of both AVP and OT.
3.1.2. Hypophysectomy
In anesthetized rats, the pituitary gland is exposed by parapharyngeal approach, and a dental 
drill is used to penetrate the base of the skull. The whole pituitary (anterior and posterior 
lobes) is then removed by suction.
Hypophysectomy (hypox) interrupts the hormonal secretion of both AVP and OT, depresses 
sodium excretion, and increases serum sodium concentration and water intake [45]. However, 
the peak sodium excretion of hypox animals treated with both neurohormones (AVP and OT) 
remains below that of intact rats, despite the synergic natriuretic effects of the combined treat-
ment. Consequently, it has been proposed that the deficit produced in some adenohypophy-
seal hormones, such as prolactin (with antidiuretic effects in animals lacking AVP [46], may 
be relevant in this type of CDI.
Besides their hormone deficit, hypox animals often show marked disorders in their body 
sodium regulation. Thus, hypox rats consumed larger amounts of NaCl solutions than intact 
rats [47], an unexpected behavior considering that these animals are hypernatremic. However, 
hypox animals maintain an adequate hydromineral regulation capacity under homeostatic 
challenges. Thus, hypox animals significantly reduced their urinary sodium outputs on low-
sodium diets [47], while hypertonic NaCl injection into the third ventricle stimulated their 
sodium excretion and antidiuresis [48, 49]. Given that these capacities could not have been 
activated by the secretion of AVP or OT, these and other data have been considered to demon-
strate the functional integrity of the renin-angiotensin-aldosterone system in hypox rats [47].
3.1.3. Mediobasal hypothalamic (MBH) lesion
Anesthetized rats are mounted on a stereotaxic frame to bilaterally apply an anodic current 
(1.5 mA) for 15 s through a stainless steel electrode insulated except at the tip. In Wistar rats, 
stereotaxic coordinates are 6.44 mm anterior to interaural line, 0.4 mm lateral to midline, and 
0.2 mm dorsal to interaural line; the extent of lesions is usually estimated by using the rat 
brain atlas of Paxinos and Watson [50]. Generally, all lesioned animals show extensive MBH 
lesions in the rostrocaudal dimension with complete damage of the median eminence region. 
However, partial injury of the arcuate (Arc), ventromedial (VM), and dorsomedial hypotha-
lamic nuclei has also been observed in most rats (Figure 4) [51–53].
MBH lesions in animals generate hypernatremia with triphasic polyuric and polydipsic CDI. 
A distinctive characteristic of MBH-lesioned animals is hyperphagia [51–53], which is not 
observed in hypox rats [54]. This greater food intake is likely attributable to damage to the 
Arc and/or VM hypothalamic nuclei [55]. From a neuroendocrine perspective, MBH lesions 
interrupt AVP, OT, and ANP secretions [49, 56, 57].
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Systemic OT administration was found to enhance sodium excretion and reduce urine excre-
tion and the standard polydipsic response of MBH-lesioned animals. However, concomitant 
food deprivation is necessary to show this effect, and OT-treated MBH animals with food 
available ad libitum showed no reduction in water intake or urine excretion. Likewise, the 
effects of OT were only observed when it was administered during the initial diabetic phase, 
not during the stable phase [51].
Hence, the regulatory capacity of MBH-lesioned animals is closely related to food availabil-
ity. Specifically, it has been observed that food deprivation generates a transient reduction in 
water intake of MBH-lesioned animals during the initial DI phase but completely annuls their 
polyuria and polydipsia during the stable DI phase [51, 52]. According to these results, MBH-
lesioned animals appear to retain some antidiuretic capacity, at least under food deprivation 
conditions. Furthermore, food deprivation on days 20–22 postsurgery was found to produce 
a lasting reduction in the hyperphagia (besides polydipsia) of MBH animals during the days 
that followed, when food was available ad libitum. This suggests that the magnitude of the 
polydipsic response observed after the food deprivation period may be related to the amount 
of food consumed. This dependence on food intake is in agreement with earlier studies sug-
gesting that the severity of the polydipsia and polyuria of DI is approximately proportional 
to the amount of sodium ingested in food [58–60].
Figure 4. Photomicrograph of coronal brain section of an MBH-lesioned animal stained with cresyl violet at 
approximately −2.56 mm caudal to bregma. Scale bar, 1 mm (Arc, arcuate nucleus; DM, dorsomedial nucleus; ME, 
median eminence; VM, ventromedial nucleus) (from Ref. [51] with permission from Elsevier).
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Given that nephrectomy, which prevents water loss, does not eliminate the polydipsic 
response of MBH-lesioned animals [61], it seems likely that this response is not exclusively a 
secondary effect of renal fluid loss. Thus, studies of hydromineral regulation in our laboratory 
have confirmed that OT administration and food deprivation can reduce water intake without 
a significant decrease in urine volume [62]. The possible importance of body sodium regula-
tion disorders in the polydipsic behavior of these diabetic animals is supported by findings 
that low-sodium diets reduce the serum sodium concentration and water intake of MBH-
lesioned animals [53] and that OT administration reduces the serum sodium concentration 
and water intake of food-deprived MBH-lesioned animals [51].
Unlike in hypox animals [48, 49], salt loading did not increase the natriuretic and antidi-
uretic responses of MBH-lesioned animals [49], suggesting an interruption of neuroendocrine 
pathways and of autonomous nervous system activity [63–65]. Nevertheless, when MBH-
lesioned animals could choose between a hypertonic NaCl solution and water, they preferen-
tially selected the saline solution [52]. These results are consistent with suggestions by other 
authors that lesions in the median eminence region might affect brain circuits that control 
body sodium levels [66].
In summary, it appears to be well established that food deprivation reduces body sodium 
accumulation and consequently the diabetic polydipsia of this animal model. Thus, the com-
bination of the natriuretic effect of OT and the food deprivation may have a normalizing effect 
on the hypernatremia of MBH animals.
3.2. Animal model of hereditary CDI: the Brattleboro rat
The standard model of hereditary CDI is the homozygous Brattleboro rat, first reported by the 
Valtin group in the 1960s [67]. This strain was developed from Long-Evans hooded rats, which 
are unable to synthesize antidiuretic hormone as an autosomal recessive trait of the AVP-
neurophysin II gene. The mutated allele encodes a normal AVP but an abnormal neurophysin 
II, which interferes with the regular transport and processing of the AVP-neurophysin II pre-
cursor molecule [39]. Homozygous Brattleboro rats, as would be expected, exhibit polyuric 
and polydipsic responses as well as chronic hypernatremia and hyperosmolality. However, 
AVPR2 is preserved in Brattleboro rats, which are therefore reactive to AVPR2 agonists [68].
Nephrectomy, which prevents renal water loss, was found to block the polydipsic response 
of Brattleboro rats after hypertonic NaCl administration, evidencing the primary character of 
polyuria in these animals [69], in contrast to the aforementioned observations in nephrecto-
mized MBH-lesioned animals [61]. Thus, it has been observed that Brattleboro rats compen-
sate for the excretion of excessive diluted urine by consuming large amounts of water [69] and 
reducing their consumption of salty solutions [70], in contrast to hypox and MBH-lesioned 
animals [47, 52].
However, various hydromineral challenges have been found to modify the renal regula-
tory capacity and hydromineral behavior of Brattleboro rats. Thus, Wilke and associates [71] 
reported reductions in urine volume and increases in urine osmolality and AQP2 channels 
after food deprivation or restriction, whereas Wideman and Murphy [72] observed a drastic 
fall in the water intake of Brattleboro animals. Conversely, hypertonic NaCl administration 
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was found to markedly increase their urinary osmolality [73–75], natriuresis [57, 73, 74], and 
water intake [69]. These preserved regulatory capacities of Brattleboro rats have been related 
to the presence of increased OT plasma levels [27, 40, 45, 73, 74, 76, 77], in contrast to the AVP 
and OT deficit of neurohypox, hypox, and MBH-lesioned animals [40, 41, 45, 49, 57].
The OT-induced antidiuretic effect in Brattleboro rats was blocked by treatment with AVPR2 
antagonist [23, 78–81] but not by OT receptor antagonist [80], suggesting that OT may act on 
AVPR2 of Brattleboro rats to activate the antidiuretic response [23, 24, 82]. However, OT does 
not appear to be the only hormone involved in the antidiuretic effects observed in Brattleboro 
rats. Morrissey et al. [46] reported that prolactin, an adenohypophyseal hormone that con-
tributes to neurohormone secretion regulation [83], reduced urinary excretion volume in 
Brattleboro but not control rats.
OT also appears to be critical for the natriuretic capacity of Brattleboro rats. Thus, the suppres-
sion of OT secretion by neurohypox greatly diminished sodium excretion rates in Brattleboro 
rats; moreover, OT administration produced a substantial and sustained natriuresis in the 
neurohypophysectomized animals [74].
Besides increasing the antidiuretic and natriuretic capacity of Brattleboro rats, OT increases 
their urine osmolality, AQP2, glomerular filtration rate, and effective filtration fraction [21, 
23, 74, 78–81, 84].
Other animal models have been developed in later studies. Thus, it has been found that muta-
tions in the AQP2 gene that interfere with its cellular processing can produce autosomal reces-
sive nephrogenic diabetes insipidus [85]. In addition, the transgenic rat TGR(ASrAOGEN)680, 
characterized by a transgene-producing antisense RNA against angiotensinogen in the brain 
and a reduced blood pressure [86], exhibits mild CDI due to a 35% reduction in plasma AVP 
and, unlike observations in Brattleboro rats, normal plasma sodium and osmolality [87]. With 
regard to the renin-angiotensin system, low-renin hypertensive animal models (e.g., trans-
genic TGR(mREN2)27 rat carrying the murine Ren-2 gene) have also proven useful [88].
4. OT and low-sodium diets as complementary treatments of CDI
At the beginning of the twentieth century, patients and animals with CDI were successfully 
treated with pituitary extracts (which supposedly contained both AVP and OT) (see Qureshi 
et al. [89] for a review). However, the observation of another oxytocic effect associated with 
those treatments (stimulation of uterine muscle contraction) reduced the use of pituitary 
extracts and of OT itself. These data, alongside the discovery of Brattleboro rats, which appar-
ently developed all DI symptoms, including blockage by nephrectomy, focused interest on 
a vasopressinergic approach to CDI [90]. Thus, it was considered that AVP deficit would be 
solely responsible for the excretion of large volumes of diluted urine (hypotonic polyuria) and 
would secondarily increase serum osmolality (hyperosmolality), serum sodium concentration 
(hypernatremia), and water intake (polydipsia). For this reason, the first-choice treatment for 
CDI patients is desmopressin (1-deamino-8-d-AVP), a synthetic analog of AVP that is selective 
for AVPR2 and exerts an even more potent regulatory effect than that of the hormone itself.
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However, many studies reviewed in this chapter appear to suggest that other hormonal com-
ponents besides AVP secretion are also interrupted, including OT in acquired CDI (the most 
frequent form). In this line, more recent studies [91] compared the effects of OT and des-
mopressin administration in CDI patients, finding that both treatments had positive effects 
on urine flow reduction, serum sodium concentration, and osmolality, and increased urine 
osmolality and urinary AQP2 excretion. Other authors also reported that the administration 
of minute amounts of pituitrin (containing AVP and OT) appears to control and improve fluid 
status with minimal adverse reactions [31]. This possible therapeutic option is consistent with 
the synergic natriuretic effect of low doses of OT and AVP observed in CDI animal models 
[40, 45]. It therefore seems plausible that the combined administration in humans of low-
dose AVP and OT would enhance their effects while minimizing oxytocic side effects. Hence, 
besides its natriuretic and antidiuretic effects [24], OT administration in patients with CDI 
may exert a valuable hyponatremic effect [82].
In cases in which relatively large brain lesions are responsible for CDI (MBH model), the 
polydipsic response cannot be understood exclusively as a secondary effect of fluid excretion, 
because it continues to be observed in animals whose polyuria is interrupted by nephrectomy 
[61]. One of the factors that may explain this hyperdipsic response is diabetic hypernatremia, 
which would also not be solely a consequence of hypotonic excretion, in agreement with 
reports that lesions in the median eminence region may affect brain circuits that control body 
sodium levels [66].
Some more recent animal studies have suggested that food deprivation or a low-sodium diet 
may be potentially useful in CDI patients, always in combination with their habitual pharma-
cological treatment. In fact, low-sodium diets are frequently prescribed for patients with AVP-
resistant or nephrogenic DI [5, 92]. These data also agree with classic studies that have indicated 
a relationship between diabetic polydipsia and dietary sodium. Thus, substances that increase 
body sodium levels were reported to exacerbate polydipsia [35, 59, 93], and, conversely, water 
intake was reduced in animals that were food deprived [59, 89] or on a low-sodium diet [59].
5. Concluding remarks
In summary, although Brattleboro rats are considered as the prototype model of CDI, the 
hydromineral characteristics of these animals do not seem to be fully comparable with an 
acquired CDI animal model. Thus, there is an AVP secretion deficit in Brattleboro rats, but OT 
remains available, whereas the CDI resulting from brain damage blocks the secretion of both 
hormones. Moreover, the symptoms and characteristics of humans and animals with aCDI 
indicate the involvement of other factors besides the habitual lack of AVP, which appear to be 
related to the neurobiological systems affected in each animal model. For instance, natriuresis 
and antidiuresis are increased after salt loading in hypox animals [48, 49] but not in MBH-
lesioned animals [49] or humans with CDI [2].
Individualized therapies that take into account of the specific neurobiological system involved 
in each type of CDI are evidently desirable to improve the quality of life of these patients. 
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However, according to the research data reviewed in this chapter, all CDI patients might 
benefit from a low-sodium diet and from OT administration or, possibly, the combination of 
low doses of AVP and OT.
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